Table 2.
Treatment and response of MM patients with PE to therapy
| Method of therapy | Number of patients | ||||
|---|---|---|---|---|---|
| Total | CR | PR | PD | DIED | |
| BDECP | 4 | 0 | 2 | 2 | 2 |
| BD | 1 | 0 | 0 | 1 | 1 |
| PAD | 7 | 0 | 2 | 5 | 5 |
| PVAD | 3 | 0 | 1 | 2 | 2 |
| PCTD | 6 | 0 | 4 | 2 | 2 |
| Chemo + local therapy | 2 | 1 | 1 | 0 | 0 |
BD, bortezomib plus dexamethasone; BDECP, bortezomib plus cisplatin, etoposide, ifosfamide, and prednisone; CR, complete response; MM, multiple myeloma; PAD, bortezomib, epirubicin, plus dexamethasone; PCTD, bortezomib, ifosfamide, thalidomide, plus dexamethasone; PD, progressive disease; PE, pleural effusion; PR, partial response; PVAD, bortezomib plus vindesine, epirubicin, and dexamethasone.